{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:14:41Z","timestamp":1790075681730,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.esmoop.2026.106961","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:07:57Z","timestamp":1777594077000},"page":"106961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world effectiveness of molecular-matched therapies in salivary gland cancer"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-7417","authenticated-orcid":false,"given":"J.A.M.","family":"Weijers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5122-6021","authenticated-orcid":false,"given":"N.J.","family":"van Ruitenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.H.","family":"van Engen-van Grunsven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.L.","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9324-7814","authenticated-orcid":false,"given":"L.A.","family":"Devriese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4181-8656","authenticated-orcid":false,"given":"M.","family":"Slingerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hoeben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.F.","family":"Oosting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H.","family":"Schreuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sewnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-9819","authenticated-orcid":false,"given":"S.","family":"van Helvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8274-7797","authenticated-orcid":false,"given":"J.A.","family":"Schalken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0227-2280","authenticated-orcid":false,"given":"G.W.","family":"Verhaegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.L.","family":"van Herpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.106961_bib1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/cdoe.13033","article-title":"Global epidemiology and socioeconomic correlates of salivary gland cancer from 2020 to 2040","volume":"53","author":"Mousavi","year":"2025","journal-title":"Community Dent Oral Epidemiol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106961_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12105-022-01420-1","article-title":"Update from the 5th Edition of the World Health Organization classification of head and neck tumors: salivary glands","volume":"16","author":"Sk\u00e1lov\u00e1","year":"2022","journal-title":"Head Neck Pathol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106961_bib3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hed.10126","article-title":"Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up","volume":"24","author":"van der Wal","year":"2002","journal-title":"Head Neck"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106961_bib4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ijc.31353","article-title":"A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from the Netherlands","volume":"143","author":"Boon","year":"2018","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106961_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jop.13395","article-title":"Clinicopathological and survival profile of patients with salivary gland myoepithelial carcinoma: a systematic review","volume":"52","author":"Lavareze","year":"2023","journal-title":"J Oral Pathol Med"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106961_bib6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoto.2013.4728","article-title":"Prognostic factors associated with decreased survival in patients with acinic cell carcinoma","volume":"139","author":"Neskey","year":"2013","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106961_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"7","author":"van Herpen","year":"2022","journal-title":"ESMO Open"},{"issue":"17","key":"10.1016\/j.esmoop.2026.106961_bib8","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of salivary gland malignancy: ASCO guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106961_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.106033","article-title":"A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers","volume":"11","author":"Alfieri","year":"2026","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106961_bib10","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/annonc\/mdx399","article-title":"Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies","volume":"28","author":"Ross","year":"2017","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2026.106961_bib11","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.3390\/cancers14174156","article-title":"Identification of fusion genes and targets for genetically matched therapies in a large cohort of salivary gland cancer patients","volume":"14","author":"Lassche","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106961_bib12","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/annonc\/mdy171","article-title":"A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors","volume":"29","author":"Ferrarotto","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106961_bib13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106961_bib14","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1093\/oncolo\/oyac080","article-title":"Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers","volume":"29","author":"Le","year":"2022","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106961_bib15","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/jjco\/hyad181","article-title":"Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies","volume":"54","author":"Takahashi","year":"2024","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106961_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106961_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106961_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70663","article-title":"Clinical outcomes with notch inhibitors in notch-activated recurrent\/metastatic adenoid cystic carcinoma","volume":"14","author":"Hoff","year":"2025","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106961_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cncy.22288","article-title":"Salivary duct carcinoma: updates in histology, cytology, molecular biology, and treatment","volume":"128","author":"Nakaguro","year":"2020","journal-title":"Cancer Cytopathol"},{"issue":"35","key":"10.1016\/j.esmoop.2026.106961_bib20","doi-asserted-by":"crossref","first-page":"59023","DOI":"10.18632\/oncotarget.19812","article-title":"Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification","volume":"8","author":"Takase","year":"2017","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.esmoop.2026.106961_bib21","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106961_bib22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hed.25035","article-title":"Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in the Netherlands","volume":"40","author":"Boon","year":"2018","journal-title":"Head Neck"},{"key":"10.1016\/j.esmoop.2026.106961_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105703","article-title":"Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma","volume":"125","author":"Uijen","year":"2022","journal-title":"Oral Oncol"},{"key":"10.1016\/j.esmoop.2026.106961_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.106297","article-title":"Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors","volume":"137","author":"Lassche","year":"2023","journal-title":"Oral Oncol"},{"key":"10.1016\/j.esmoop.2026.106961_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2021.10.033","article-title":"Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and\/or metastatic salivary gland cancer","volume":"161","author":"van Boxtel","year":"2022","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.esmoop.2026.106961_bib26","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.7150\/thno.99035","article-title":"Lutetium-177-PSMA therapy for recurrent\/metastatic salivary gland cancer: a prospective pilot study","volume":"14","author":"van Ruitenbeek","year":"2024","journal-title":"Theranostics"},{"issue":"16","key":"10.1016\/j.esmoop.2026.106961_bib27","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1158\/1078-0432.CCR-24-3581","article-title":"A phase I dose escalation and cohort expansion study of CB307, a trispecific humabody against PSMA, CD137, and albumin in patients with PSMA-positive solid tumors","volume":"31","author":"de Bono","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.106961_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2022.06.012","article-title":"High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: results from the phase 2 multicenter POSITION20 trial","volume":"170","author":"Zwierenga","year":"2022","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106961_bib29","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106961_bib30","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106961_bib31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"7776","key":"10.1016\/j.esmoop.2026.106961_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","article-title":"The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"van der Velden","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2026.106961_bib33","doi-asserted-by":"crossref","first-page":"S1227","DOI":"10.1016\/j.annonc.2024.08.2275","article-title":"LBA36: a randomised phase II study to evaluate the efficacy and safety of androgen deprivation therapy (ADT) vs chemotherapy (CT) in patients with recurrent and\/or metastatic, androgen receptor (AR) expressing, salivary gland cancers","volume":"35","author":"Licitra","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106961_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221119538","article-title":"Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma","volume":"14","author":"Kawakita","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106961_bib35","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/ijc.32795","article-title":"Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients","volume":"146","author":"van Boxtel","year":"2020","journal-title":"Int J Cancer"},{"issue":"14","key":"10.1016\/j.esmoop.2026.106961_bib36","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.3390\/cancers13143527","article-title":"Predictive and prognostic biomarker identification in a large cohort of androgen receptor-positive salivary duct carcinoma patients scheduled for combined androgen blockade","volume":"13","author":"Lassche","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"34","key":"10.1016\/j.esmoop.2026.106961_bib37","doi-asserted-by":"crossref","first-page":"35542","DOI":"10.18632\/oncotarget.4689","article-title":"Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer","volume":"6","author":"Perner","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106961_bib38","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41379-020-0576-2","article-title":"Molecular patterns in salivary duct carcinoma identify prognostic subgroups","volume":"33","author":"Mueller","year":"2020","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106961_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106961_bib40","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.106961_bib41","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106961_bib42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2159-8290.CD-24-0306","article-title":"Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers","volume":"15","author":"Wilding","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2026.106961_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107280","article-title":"The impact of HER2-low expression in salivary duct carcinoma: clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy","volume":"165","author":"Kano","year":"2025","journal-title":"Oral Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106961_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100273","article-title":"ERBB2 amplification and HER2 expression in salivary duct carcinoma: evaluation of scoring guidelines and potential for expanded anti-HER2 therapy","volume":"36","author":"McAfee","year":"2023","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106961_bib45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41698-022-00324-1","article-title":"Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling","volume":"6","author":"Kohsaka","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.106961_bib46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12967-014-0299-6","article-title":"High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma","volume":"12","author":"Ku","year":"2014","journal-title":"J Transl Med"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106961_bib47","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106961_bib48","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.6004\/jnccn.2018.7056","article-title":"First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition","volume":"16","author":"Lin","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106961_bib49","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1038\/s41591-023-02518-x","article-title":"Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial","volume":"29","author":"Vos","year":"2023","journal-title":"Nat Med"},{"issue":"6411","key":"10.1016\/j.esmoop.2026.106961_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106961_bib51","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106961_bib52","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-19-3758","article-title":"The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype","volume":"26","author":"Linxweiler","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106961_bib53","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review","volume":"12","author":"Laurie","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106961_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100371","article-title":"Analysis of B7-H4 expression across salivary gland carcinomas reveals adenoid cystic carcinoma-specific prognostic relevance","volume":"37","author":"Siqueira","year":"2024","journal-title":"Mod Pathol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926009038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926009038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:12:28Z","timestamp":1780290748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926009038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2059702926009038"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106961","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of molecular-matched therapies in salivary gland cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106961","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106961"}}